Pulmonary drug delivery. Part II: the role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications.
Research in the area of pulmonary drug delivery has gathered momentum in the last several years, with increased interest in using the lung as a means of delivering drugs systemically. Advances in device technology have led to the development of more efficient delivery systems capable of delivering larger doses and finer particles into the lung. As more efficient pulmonary delivery devices and sophisticated formulations become available, physicians and health professionals will have a choice of a wide variety of device and formulation combinations that will target specific cells or regions of the lung, avoid the lung's clearance mechanisms and be retained within the lung for longer periods. It is now recognized that it is not enough just to have inhalation therapy available for prescribing; physicians and other healthcare providers need a basic understanding of aerosol science, inhaled formulations, delivery devices, and bioequivalence of products to prescribe these therapies optimally.
Labiris
N R
NR
Department of Medicine, McMaster University, Hamilton, Ontario, Canada. labir@mcmaster.ca
Dolovich
M B
MB
D000280:Administration, Inhalation; D000336:Aerosols; D001673:Biodegradation, Environmental; D002626:Chemistry, Pharmaceutical; D004337:Drug Carriers; D006801:Humans; D036501:Metered Dose Inhalers; D009330:Nebulizers and Vaporizers; D010316:Particle Size; D004364:Pharmaceutical Preparations / Q000008:administration & dosage*; D011208:Powders; D013810:Therapeutic Equivalency
D000336:Aerosols; D004337:Drug Carriers; D004364:Pharmaceutical Preparations; D011208:Powders